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Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for
prognostic association of circulating tumor cells in gastroesophageal cancer
Abstract
AIM
AIM: To demonstrate the feasibility of cryopreservation of peripheral blood mononuclear cells (PBMCs)
for prognostic circulating tumor cell (CTC) detection in gastroesophageal cancer.
METHODS
METHODS: Using 7.5 mL blood samples collected in EDTA tubes from patients with gastroesopheagal
adenocarcinoma, CTCs were isolated by epithelial cell adhesion molecule based immunomagnetic
capture using the IsoFlux platform. Paired specimens taken during the same blood draw (n = 15) were
used to compare number of CTCs isolated from fresh and cryopreserved PBMCs. Blood samples were
processed within 24 h to recover the PBMC fraction, with PBMCs used for fresh analysis immediately
processed for CTC isolation. Cryopreservation of PBMCs lasted from 2 wk to 25.2 mo (median 14.6 mo).
CTCs isolated from pre-treatment cryopreserved PBMCs (n = 43) were examined for associations with
clinicopathological variables and survival outcomes.
RESULTS
RESULTS: While there was a significant trend to a decrease in CTC numbers associated with
cryopreserved specimens (mean number of CTCs 34.4 vs 51.5, P = 0.04), this was predominately in
samples with a total CTC count of > 50, with low CTC count samples less affected (P = 0.06). There was
no significant association between the duration of cryopreservation and number of CTCs. In
cryopreserved PBMCs from patient samples prior to treatment, a high CTC count ( > 17) was associated
with poorer overall survival (OS) (n = 43, HR = 4.4, 95%CI: 1.7-11.7, P = 0.0013). In multivariate analysis,
after controlling for sex, age, stage, ECOG performance status, and primary tumor location, a high CTC
count remained significantly associated with a poorer OS (HR = 3.7, 95%CI: 1.2-12.4, P = 0.03).
CONCLUSION
CONCLUSION: PBMC cryopreservation for delayed CTC isolation is a valid strategy to assist with sample
collection, transporting and processing.

Disciplines
Medicine and Health Sciences

Publication Details
Brungs, D., Lynch, D., Luk, A. W. S., Minaei, E., Ranson, M., Aghmesheh, M., Vine, K. L., Carolan, M., Jaber,
M., de Souza, P. & Becker, T. M. (2018). Cryopreservation for delayed circulating tumor cell isolation is a
valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer. World
Journal of Gastroenterology, 24 (7), 810-818.

Authors
Daniel Brungs, David Lynch, Alison Luk, Elahe Minaei, Marie Ranson, Morteza Aghmesheh, Kara L. Vine,
Martin G. Carolan, Mouhannad Jaber, Paul de Souza, and Therese M. Becker

This journal article is available at Research Online: https://ro.uow.edu.au/ihmri/1211

World J Gastroenterol 2018 February 21; 24(7): 810-818

Submit a Manuscript: http://www.f6publishing.com
DOI: 10.3748/wjg.v24.i7.810

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

ORIGINAL ARTICLE
Basic Study

Cryopreservation for delayed circulating tumor cell isolation
is a valid strategy for prognostic association of circulating
tumor cells in gastroesophageal cancer
Daniel Brungs, David Lynch, Alison WS Luk, Elahe Minaei, Marie Ranson, Morteza Aghmesheh, Kara L Vine,
Martin Carolan, Mouhannad Jaber, Paul de Souza, Therese M Becker
Institutional review board statement: This study was
approved by South Western Sydney Local Health District Human
Research Ethics Committee (Project Number 15/072). A written
informed consent was obtained from each participant before
sample collection.

Daniel Brungs, Elahe Minaei, Marie Ranson, Morteza
Aghmesheh, Kara L Vine, Martin Carolan, Illawarra Health
and Medical Research Institute, University of Wollongong,
Wollongong 2500, Australia
Daniel Brungs, Elahe Minaei, Marie Ranson, Kara L Vine,
School of Biological Sciences, University of Wollongong,
Wollongong 2500, Australia

Conflict-of-interest statement: All authors have no conflicts of
interest to declare.

Daniel Brungs, Morteza Aghmesheh, Martin Carolan,
Mouhannad Jaber, Illawarra Cancer Centre, Wollongong
Hospital, Wollongong 2500, Australia

Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was
selected by an in-house editor and fully peer-reviewed by external
reviewers. It is distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this
work non-commercially, and license their derivative works on
different terms, provided the original work is properly cited and
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/

Daniel Brungs, David Lynch, Alison WS Luk, Elahe Minaei,
Marie Ranson, Morteza Aghmesheh, Kara L Vine, Martin
Carolan, Mouhannad Jaber, Paul de Souza, Therese M
Becker, CONCERT-Translational Cancer Research Centre, New
South Wales 2000, Australia
David Lynch, Paul de Souza, Therese M Becker, Centre
for Circulating Tumor Cell Diagnostics and Research, Ingham
Institute for Applied Medical Research, Liverpool Hospital,
Sydney 2170, Australia

Manuscript source: Unsolicited manuscript
Correspondence to: Daniel Brungs, BSc, MBBS, Doctor,
Illawarra Cancer Care Centre, Wollongong Hospital, 348 Crown
St, Wollongong NSW 2500,
Australia. daniel.brungs@health.nsw.gov.au
Telephone: +61-2-42225200
Fax: +61-2-42225243

Paul de Souza, Therese M Becker, School of Medicine,
University of Western Sydney, Sydney 2170, Australia
Paul de Souza, Therese M Becker, South Western Medical
School, University of New South Wales, Sydney 2170, Australia
ORCID number: Daniel Brungs (0000-0002-8154-6966);
David Lynch (0000-0002-9589-4478); Alison WS Luk
(0000-0003-1221-7023); Elahe Minaei (0000-0002-8674-6801);
Marie Ranson (0000-0002-5570-9645); Morteza Aghmesheh
(0000-0003-1664-4743); Kara L Vine (0000-0001-6871-1149);
Martin Carolan (0000-0001-6671-029X); Mouhannad Jaber
(0000-0001-6991-9507); Paul de Souza (0000-0002-7380-1170);
Therese M Becker (0000-0002-5636-9902).

WJG|www.wjgnet.com

Received: November 6, 2017
Peer-review started: November 7, 2017
First decision: November 30, 2017
Revised: December 11, 2017
Accepted: December 19, 2017
Article in press: December 19, 2017
Published online: February 21, 2018

810

February 21, 2018|Volume 24|Issue 7|

Brungs D et al . Cryopreservation of PBMCs for CTC isolation

Abstract

circulating tumor cell (CTC) enumeration from cryopre
served peripheral blood mononuclear cells. Cryopre
servation may assist with the wider incorporation of
CTC collection and analysis in biobanking, retrospec
tive studies, and large international clinical trials, by
facilitating specimen storage, bulk transporting, and
batch processing.

AIM
To demonstrate the feasibility of cryopreservation
of peripheral blood mononuclear cells (PBMCs) for
prognostic circulating tumor cell (CTC) detection in
gastroesophageal cancer.
METHODS
Using 7.5 mL blood samples collected in EDTA tubes
from patients with gastroesopheagal adenocarcinoma,
CTCs were isolated by epithelial cell adhesion molecule
based immunomagnetic capture using the IsoFlux
platform. Paired specimens taken during the same
blood draw (n = 15) were used to compare number
of CTCs isolated from fresh and cryopreserved PBMCs.
Blood samples were processed within 24 h to recover
the PBMC fraction, with PBMCs used for fresh analysis
immediately processed for CTC isolation. Cryopre
servation of PBMCs lasted from 2 wk to 25.2 mo
(median 14.6 mo). CTCs isolated from pre-treatment
cryopreserved PBMCs (n = 43) were examined for
associations with clinicopathological variables and
survival outcomes.

Brungs D, Lynch D, Luk AW, Minaei E, Ranson M, Aghmesheh
M, Vine KL, Carolan M, Jaber M, de Souza P, Becker TM.
Cryopreservation for delayed circulating tumor cell isolation
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2018; 24(7): 810-818 Available from: URL: http://www.
wjgnet.com/1007-9327/full/v24/i7/810.htm DOI: http://dx.doi.
org/10.3748/wjg.v24.i7.810

INTRODUCTION
Circulating tumor cell (CTC) analysis continues to be a
rapidly developing field in oncology, offering a promising
tool to both prognosticate and guide managements for
[1]
patients . Despite recent advancements in the field,
one persisting challenge to the widespread adoption
of CTC analysis for translational clinical trials or routine
clinical care is the limited time frame considered
best for blood processing and CTC isolation. Usually
fresh blood is processed for CTCs within 24 h after
blood draw, requiring prompt transfer to specialised
centres for CTC isolation and analysis, which offers
[2]
significant logistical challenges . To overcome this
issue, some studies use blood collection tubes that
contain fixatives. Fixation of blood samples can allow
CTC processing delayed by several days which has
[3,4]
proven very useful for some CTC analyses . However,
fixatives may interfere with down-stream molecular
[5]
analyses that require isolation of nucleic acids . An
alternative is the use of cryopreservation protocols for
peripheral blood mononuclear cells (PBMCs) to allow
delayed CTC isolation from these cells followed by CTC
analysis. Cryopreservation should overcome fixation
related analysis limitations and allow far more flexible
time frames for batched CTC processing. However, a
defined, robust cryopreservation protocol that is proven
to enable analysis of the same or at least a relevant
proportion of CTCs to that found in fresh samples,
needs to be adopted and confirmation is needed
whether cryopreserved CTCs can still predict disease
outcome.
The advantage of cryopreservation of PBMCs is that
it requires only minimal local processing, possible in
most diagnostic settings, as well as feasible cryostorage
and frozen transport of PBMC samples.
While there are a large number of approaches used
to isolate and identify circulating tumor cells (recently

RESULTS
While there was a significant trend to a decrease in
CTC numbers associated with cryopreserved specimens
(mean number of CTCs 34.4 vs 51.5, P = 0.04), this
was predominately in samples with a total CTC count
of > 50, with low CTC count samples less affected (P
= 0.06). There was no significant association between
the duration of cryopreservation and number of CTCs.
In cryopreserved PBMCs from patient samples prior
to treatment, a high CTC count (> 17) was associated
with poorer overall survival (OS) (n = 43, HR = 4.4,
95%CI: 1.7-11.7, P = 0.0013). In multivariate analysis,
after controlling for sex, age, stage, ECOG performance
status, and primary tumor location, a high CTC count
remained significantly associated with a poorer OS (HR
= 3.7, 95%CI: 1.2-12.4, P = 0.03).
CONCLUSION
PBMC cryopreservation for delayed CTC isolation is a
valid strategy to assist with sample collection, trans
porting and processing.
Key words: Cryopreservation; Circulating tumor cells;
Liquid biopsy; Gastroesophageal cancer; Gastric cancer
© The Author(s) 2018. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: This study demonstrates a novel and robust
protocol for the cryopreservation and thawing of patient
blood samples, demonstrating reliable circulating tumor
cell isolation and characterisation after the long term
storage of patient samples. Using the largest patient
cohort reported to date, we validated our method by
confirming the independent prognostic association of
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[6]

reviewed by van der Toom et al ), the best established
TM
and most widely used is the CellSearch system
(Menarini-Silicon Biosystems), which uses positive
immunomagnetic isolation of epithelial cell adhesion
molecule (EpCAM, an epithelial cell marker) expressing
cells followed by cytokeratin (CK), CD45, and DAPI
[2]
staining . The CTCs are then identified with automated
immunofluorescence microscopy, defined by an EpCAM/
CK/DAPI positive and CD45 negative phenotype. Cell
Search CTC counts have shown to be prognostic in
[7-9]
large patient series in a variety of cancers , including
[10-12]
gastroesophageal cancer
, but the instrument offers
limited sensitivity in resectable gastroesophageal cancer,
[10,13]
with CTCs detected in less than 15% of patients
.
The IsoFlux system (Fluxion) uses a similar definition
of CTCs to CellSearch (EpCAM/CK/DAPI positive,
CD45 negative phenotype), but has shown a greater
[14-16]
sensitivity for CTC detection
. This platform uses
EpCAM targeted immunomagnetic isolation of CTCs
within a microfluidic setting, improving isolation of CTCs
with lower EpCAM expression, minimising leukocyte
contamination, and allowing downstream applications
including staining, enumeration, or sequencing, as
[16]
shown for fresh blood samples .
Here, we use a viable method of PBMC cryopre
servation that allows subsequent isolation and immu
nocytochemical analysis of CTCs. We demonstrate
the feasibility of PBMC cryopreservation for delayed
CTC isolation using paired cryopreserved and freshly
processed blood samples drawn at the same time
from patients with gastroesophageal adenocarcinoma.
Importantly, we also provide data confirming that
cryopreserved CTCs remain clinically applicable as a
circulating prognostic marker for overall survival (OS).

participant before sample collection.

Sample preparation

Blood samples were processed within 24 h to recover
the PBMC fraction using 50 mL SepMate tubes and
Lymphoprep according to manufacturer’s instructions
(Stemcell Technologies, Vancouver, BC, Canada).
PBMCs used for fresh analysis were resuspended in
Isoflux Binding Buffer and immediately processed for
CTC isolation (see below).
PBMCs for cryopreservation were well resuspended
in 1 mL of diluted plasma (the supernatant of the
PBMC preparation from the matching patient) with the
addition of 7.5% final DMSO, and stored at -80 ℃ until
further processing. Cryopreserved samples were thawed
according to the protocol from Fluxion Biosciences, San
[17]
Francisco, California, United States . In brief, warmed
(37 ℃) thawing buffer, consisting of RPMI 1640 with
10% Fetal Bovine Serum (FBS, Bovogen Biologicals,
Australia) and 50 Unit/mL Benzonase (Sigma-Aldrich,
Germany), was added to thawed samples, washed once
in thawing buffer, and resuspended in IsoFlux Binding
Buffer with 5% FBS.

Circulating tumor cell isolation, staining, and imaging

As per the Fluxion protocol, immunomagnetic beads
preconjugated with anti-EpCAM antibodies (CTC
Enrichment Kit; Fluxion Biosciences Inc) were added
to PBMCs suspended in IsoFlux Binding Buffer, and
incubated for 90 min at 4 ℃ with passive mixing on a
rotator. Samples were then loaded into the sample well
of the microfluidic cartridge and underwent immuno
magnetic isolation of CTCs with the IsoFlux using the
standard protocol (Fluxion Biosciences Inc).
Recovered CTCs were blocked with a final concen
tration of 1.2 µg/µL mouse IgG in binding buffer (Jackson
ImmunoResearch, Baltimore, PA, United States) for
30 min, washed and fixed in fixing solution (Fluxion
Biosciences Inc). The CTCs were then blocked in 10%
FBS in binding buffer for 15 min, then underwent immu
nofluorence staining for anti-CD45 antibody conjugated
to Alexa Fluor 647 (Biolegend, Clone HI30). The
CTCs were also stained for urokinase plasminogen
activator receptor (uPAR, CD87), a key receptor in the
plasminogen activator system and clinically relevant
[18]
biomarker in primary gastroesophageal cancer , using
anti-uPAR antibody conjugated to AF594 (ThermoFischer,
Clone R4). After permeabilization with 0.1% Triton
X-100, cells were probed with anti-cytokeratin antibody
conjugated to FITC (Sigma-Aldrich, Clone PCK-26). CTCs
were finally stained with Hoechst and mounted using
Isoflux mounting media to 24-well glass bottom plates
(MoBioTec, Goettingen, Germany) for imaging.
Imaging was performed with an inverted epifluo
rescence microscope (Leica DMi8, Leica Microsystems
Pty Ltd) using the Leica Application Suite. Cells were
considered CTCs if they were CK positive, CD45

MATERIALS AND METHODS
Patient population

Blood samples were collected from patients with
histologically confirmed distal oesophageal, gastroe
sophageal junction, or gastric adenocarcinomas treated
at Wollongong Hospital, Australia. Blood samples were
collected in 7.5 mL EDTA Vacutainer tubes (Sarstedt
AG & Co.) and maintained at room temperature until
processing.
In the initial cohort (Cohort 1) to confirm the feasi
bility of cryopreservation, 15 patients with gastroe
sophageal carcinomas had 2 specimens taken during
the one blood draw, one processed within 24 h (“fresh”
specimen), and one cryopreserved with delayed CTC
isolation and analysis (“cryopreserved” specimen). Pretreatment blood samples were cryopreserved from a
second, larger cohort of patients for correlation with
clinical outcomes (Cohort 2). The study was approved
by South Western Sydney Local Health District Human
Research Ethics Committee (Project Number 15/072).
A written informed consent was obtained from each
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DAPI

CK

CD45

uPAR

Merged

Fresh

Cryopreserved

20 μm

Figure 1 Representative images of circulating tumor cell isolation from fresh and cryopreserved samples demonstrating preservation of leukocyte and
circulating tumor cell morphology. The fresh sample demonstrates a nucleated CK+/CD45- CTC which is uPAR negative, as well as a CK-/CD45+ leukocyte. The
cryopreserved sample shows a uPAR positive CTC. CTC: Circulating tumor cell.

negative, nucleated and morphologically intact. The
proportion of uPAR positive CTCs was recorded.

similar to fresh samples (Figure 1). There was a
significant difference between CTC numbers isolated
from the cryopreserved samples compared to fresh
samples (mean number of CTCs 34.4 cryopreserved vs
51.5 fresh, P = 0.04, Figure 2), however this difference
was predominately attributable to a larger fall in CTC
numbers in samples with very high CTC counts (> 50
CTCs in the fresh specimen). There was no significant
difference in CTC count between cryopreserved and
fresh samples for specimens with CTC count less than
50 (n = 11 patients, mean number of CTCs 10.7 vs
16.3, P = 0.06). Thus CTC loss by cryopreservation in
patient samples with low CTC counts appears relatively
minor (mean proportion of CTCs lost in cryopreserved
samples = 23.95%).

Statistical analysis

The CTC recovery from matched cryopreserved and
fresh samples were compared with the paired t-test.
Correlation between cryopreservation time and CTC
number was described with a Pearson correlation
coefficient, and the Fisher exact test and t-test were
used to compare the status of CTCs with categorical
clinicopathologic factors.
For survival analyses, in the absence of established
cut-offs for prognostic CTC numbers, the median CTC
count (17) was used as the discriminator between high
and low CTC counts. Survival analyses are conducted
using Kaplan-Meier methods, with median survival
reported. Unadjusted and multivariable Cox proportional
hazards regression analyses were used to estimate the
association between CTC counts and survival, and to
calculate corresponding hazard ratios (HRs) and 95%
confidence intervals (CIs). The following variables were
included in the multivariate model: age, sex, ECOG,
TNM stage, primary tumor location, and CTC count.
All statistical analyses were performed using SAS 9.2
software (SAS Institute, Inc., Cary, NC, United States).

Cryopreserved circulating tumor cell and clinical
outcomes (cohort 2)

A larger cohort of 43 gastroesophageal cancer
patients (cohort 2) was analyzed to validate whether
detectable CTC counts post cryopreservation correlated
to disease outcomes. All patient samples were taken
prior to treatment commencement and had undergone
cryopreservation before CTC isolation. Cohort 2 included
the 10 treatment naive patients from cohort 1. Patient
characteristics of cohort 2 are summarised in Table 1.
Twenty-four patients had resectable disease (Stage
Ⅱ or Ⅲ). Post CTC evaluation, 11 of these patients
received neoadjuvant chemoradiotherapy prior to
resection (CROSS regimen), 3 received perioperative
chemotherapy (MAGIC regimen), and 10 had surgery
alone. Nineteen patients had metastatic disease (stage
Ⅳ). Most of these patients received chemotherapy
(7 patients: platinum and capecitabine doublet, 3
patients: anthracycline, capecitabine, and platinum
triplet, 1 patient: irinotecan or paclitaxel monotherapy),
immunotherapy (2 patients), and 6 patients received no
active systemic treatments.
CTCs were detected in 42/43 patients (95.5%),

RESULTS
Matched fresh and cryopreserved specimens (cohort 1)

Matching parallel blood samples, collected from 15
gastroesophageal cancer patients (10 patients had
blood taken prior to treatment, 5 patients were already
on treatment), that had either been cryopreserved
before CTC processing or were processed fresh, were
compared. Cryopreservation of PBMCs lasted from 2 wk
to 25.2 mo (median 14.6 mo). There was no significant
correlation between cryopreservation time and CTC
number (Pearson r -0.25, P = 0.09). CTCs isolated
from cryopreserved samples appeared morphologically
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Table 1 Characteristics of patients in cohort 2 n (%)
CTC count

Age
Mean (range)
Sex
Male
Female
ECOG
0-1
2-4
Primary tumor location
Distal oesophageal
Gastroesophageal junction
Gastric
Stage
Ⅱ
Ⅲ
Ⅳ

All patients

Low (CTC ≤ 17)

High (CTC > 17)

n = 43

n = 23

n = 20

64 (39-89)

65 (39-89)

64 (48-83)

32 (74.4)
11 (25.6)

15 (65.2)
8 (34.8)

20 (85.0)
3 (15.0)

36 (83.7)
7 (16.3)

22 (95.6)
1 (4.3)

14 (70.0)
6 (30.0)

12 (27.9)
14 (32.6)
17 (37.5)

8 (34.8)
4 (17.4)
11 (47.8)

4 (20.0)
10 (50.0)
6 (30.0)

18 (41.9)
6 (14.0)
19 (44.2)

13 (56.5)
4 (17.4)
6 (26.1)

5 (25.0)
2 (10.0)
13 (65.0)

CTC: Circulating tumor cell; ECOG: Eastern cooperative oncology group performance status.

250

200
150
Number of CTCs

CTC count

200

150

100
50
0

100

-50
Localised

50

Figure 3 Circulating tumor cell count by stage. CTC processing post
cryopreservation produced a higher mean CTC count in metastatic patients
compared to the resectable patients (mean CTC in metastatic 53.8 vs
resectable 15.8, P = 0.0013). CTC: Circulating tumor cell.

0
Fresh

Cryopreserved

Figure 2 Circulating tumor cell enumeration by processing method.
Mean number of CTCs isolated in the fresh specimens were higher than in the
matched cryopreserved sample (mean difference in CTCs 17.1 95%CI: 0.7-33.6,
P = 0.043). This difference was mostly driven by larger falls in CTC counts in
samples with high numbers of CTCs (> 50 CTCs in fresh samples), with no
significant difference in CTC counts for samples with less than 50 CTC in the
fresh specimen (P = 0.06).

1.7-11.7, P = 0.0013). In multivariate analysis, after
controlling for sex, age, stage, ECOG performance
status, and primary tumor location, a high CTC count
remained an independent prognostic factor associated
with poor OS (Table 2, HR = 3.7, 95%CI: 1.2-12.4,
P = 0.03). This association was stronger when the
analysis was restricted to patients with metastatic
disease (n = 19, HR = 5.5, 95%CI: 1.2-25.5, P = 0.01),
but not observed in patients with resectable disease
(n = 24, P = 0.39), although a high CTC count (> 17)
was associated with a non-significant trend to shorter
recurrence free survival in these patients (HR = 3.1,
95%CI: 0.8-12.6, P = 0.09).
Most patients had some uPAR positive CTCs (40/43,
93.0%), however the proportion of uPAR positive CTCs
was similar between patients with localised and meta
static disease (mean proportion uPAR positive CTCs
48.8% vs 47.7% respectively, P = 0.89), and there was
no association with survival outcomes (Supplementary

with a median CTC of 17 (interquartile range 8-38).
Patients with metastatic disease had a higher number
of CTCs than those with resectable disease (Figure 3,
mean CTC count 53.8 vs 15.8, P = 0.0013).
Currently there are no established cut-offs for
prognostic CTC numbers detected using the IsoFlux
in gastroesophageal adenocarcinoma. Therefore we
opted to divide our patients by their CTC counts, above
versus equal or lower than the median CTC count,
to test for any correlation with clinical outcomes.
Patients with a high CTC count (> 17) had a poorer
OS than those with a lower CTC count (≤ 17) (Figure
4, median OS 2.8 mo vs 23.2 mo, HR = 4.4, 95%CI:

WJG|www.wjgnet.com
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Table 2 Univariate and multivariate analysis for overall survival for cohort 2 (n = 43)
Univariate

Multivariate

Factor

HR (95%CI)

P value

HR (95%CI)

P value

CTC count (high vs low)
Age (≥ 65 vs <65 yr old)
ECOG (2-4 vs 0-1)
Sex (male vs female)
Stage (Ⅳ vs Ⅱ-Ⅲ)
Primary tumor location (gastric vs oesophageal/GOJ)

4.4 (1.7-11.7)
0.7 (0.3-1.8)
7.2 (2.2-23.7)
1.2 (0.4-3.8)
10.0 (3.3-30.8)
0.3 (0.1-1.01)

0.001
0.46
0.0002
0.7
< 0.0001
0.05

3.7 (1.2-12.4)
1.0 (0.9-1.1)
2.3 (0.5-10.1)
0.7 (0.2-2.1)
9.9 (2.9-33.8)
0.4 (0.2-1.6)

0.03
0.76
0.14
0.49
0.0003
0.22

Significant values are italicised. In both univariate and multivariate analysis, a high CTC count (> 17) remained statistically significant as an independent
factor associated with poorer overall survival. CTC: Circulating tumor cell; ECOG: Eastern cooperative oncology group performance status; GOJ:
Gastroesophageal junction.

central processing. This would be a huge benefit for
larger scale clinical trials as it would allow inclusion of
geographically separated sites.
Previous work has shown that the immunochemical
properties of CK, EpCAM and CD45, central to the
isolation and identification of CTCs, are not affected
[20,21]
by cryopreservation and thawing
. In agreement,
our results demonstrate a similar morphological and
immunofluorescent profile between cryopreserved
and fresh CTCs and leukocytes, suggesting current
techniques are suitable for cryopreserved samples.
This approach is further supported by other work
showing close concordance in genetic alterations seen
[21]
on paired fresh and frozen CTCs .
Our results also show that enumeration of CTCs
isolated from cryopreserved PMBCs is a valid prognostic
biomarker in gastroesophageal cancer. Patients with
metastatic disease had a significantly higher number
of CTCs than those with resectable disease (mean CTC
count 53.8 vs 15.8, P = 0.0013). Moreover, patients
with a high CTC count (> 17) had a much poorer OS
than those with a lower CTC count (≤ 17) (HR = 4.4,
P = 0.0013). High CTC count remained significant in
the multivariate analysis as an independent predictor
of poorer OS (HR = 3.7, P = 0.03), after controlling for
age, ECOG, sex, stage and primary tumour location,
particularly when analysis was restricted to patients with
metastatic disease only (HR = 5.5, P = 0.01). These
results are concordant with other studies which confirm
CTC enumeration as an important prognostic factor in
[10-12]
gastroesophageal cancer
.
Given our previous findings that the uPA system is a
clinically relevant biomarker in primary gastroesophageal
[18]
cancer , we undertook and successfully probed for
uPAR expression in CTCs derived from cryopreserved
and fresh samples. We previously have shown that
higher expression of uPA, uPAR and PAI-1 in the
primary tumour is associated with higher risk disease
and poorer prognosis. However, in this study, there
was no correlation between CTC uPAR expression with
disease parameters. This suggests that the selection of
epithelial (EpCAM-positive) CTCs might have affected
any correlation of uPAR with patient outcome, as
CTCs that present mesenchymal phenotypes, such as

Percent survival

100

50

≤ 17 CTC
> 17 CTC
0

0

6

12

18

24

t /mo

Figure 4 Overall survival by circulating tumor cell count. Patients with >
17 CTCs isolated from cryopreserved specimens had a poorer overall survival
compared to those with ≤ 17 CTCs (median OS 2.8 mo vs 23.2 mo, HR = 4.4,
95%CI: 1.7-11.7, P = 0.0013). OS: Overall survival; CTC: Circulating tumor cell.

Figure 1, median OS 17.0 mo vs 12.8 mo, P = 0.6).

DISCUSSION
In this study we report the reliable isolation, immuno
cytochemical identification, and enumeration of gastroe
sophageal cancer CTCs from cryopreserved PBMCs
using the IsoFlux platform. The included cohort is the
largest reported study analysing cryopreservation of
patient PBMCs for CTC detection. Our data confirms
that CTCs isolated from cryopreserved samples remain
an independent prognostic factor associated with OS.
The timely processing of patient samples for CTC
isolation, usually is recommended within 24 h for most
[19]
isolation methods , presenting significant logistical
challenges for researchers and prohibits inclusion of
patients from remote areas into clinical trials that would
rely on CTCs as outcome measures. This is mainly be
cause current methods of CTC analysis require signifi
cant expertise, instrumentation, time and laboratory
resources, usually performed in specialised research
centres. Protocols using isolation of CTCs from cryop
reserved specimens would require some basic proces
sing and cryopreservation at the site of blood draw, but
offer many advantages, including the ability to biobank
patient samples for prolonged periods of time before
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uPAR expressing cells, can escape standard methods
[22]
of isolation reliant on epithelial markers . Indeed
[23]
Vishnoi et al . has previously reported the isolation
of subsets of EpCAM-negative, uPAR and integrin β1
positive breast cancer CTCs, which further supports the
[23]
concept of CTC heterogeneity . Ultimately, we have
successfully stained for a novel biomarker, uPAR, which
further supports our cryopreservation method as a valid
CTC isolation approach.
One important concern with cryopreservation is the
potential for loss of CTCs due to cell loss during freezing,
[20]
storage, or thawing. In a study by Nejlund et al , tumor
cell recovery from cryopreserved spiked tumor cells in
normal controls was variable, with up to a 40% tumor
cell loss. However in clinical samples using matched
fresh and cryopreserved specimens from the same
patient, there was no consistent loss of CTCs, with the
variation in CTC enumeration similar to those seen in
[2,20]
paired fresh samples in other studies
. Friedlander
[21]
et al
found that cryopreservation of PBMCs had no
significant effect on the cell recovery from patients with
metastatic prostate cancer. We noted a small loss of
CTCs associated with cryopreservation, however this
was predominately in samples with large numbers
of CTCs (> 50), where loss of some CTCs is more
acceptable than samples with low CTC counts. We
noted samples with high numbers of CTCs were more
prone to cell clumping despite benzonase. This is
normally due to the release of viscous DNA from cell
lysis on thawing, leading to aggregates which prevent
accurate CTC counting. We speculate that the higher
disease burden in these patients, coupled with a
corresponding systemic inflammatory response, lead
to poorer cell integrity within the PBMCs of high CTCcount samples. Some loss of CTCs in these samples
will have little impact for prognostic and down-stream
biomarker analysis purposes. There was no significant
loss of CTCs in samples were the total CTC count was
≤ 50 (P = 0.06).
Similar to previously published work, we found that
the duration of cryopreservation was not correlated
[20]
with number of isolated CTCs . Moreover, we were
able to isolate CTCs from specimens stored at -80 ℃
for over two years, suggesting cryopreservation is a
suitable approach for long term projects that involve
biobanking of patient samples.
Even when using cryopreservation prior to CTC
isolation, we found higher numbers of CTCs (median
CTC count 17) and a higher number of patient samples
with CTCs (98%) compared to other studies using
EpCAM based CTC capture in gastroesophageal
[10-12,24]
cancer
. The correlation of CTC numbers with
disease progression implies that the CTCs we identified
are indeed disease related. Increased CTC counts
are consistent with the higher reported sensitivity
of the IsoFlux system compared to other platforms,
particularly in isolating CTCs with a lower expression of
[14-16]
EpCAM
. Our results confirm, in the largest cohort
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of patients reported to date, that a high CTC count (>
17) in cryopreserved specimen was an independent
prognostic factor associated with poorer OS (HR =
3.7). As expected from the minimal CTC loss during
cryopreservation, these data indicate that indeed
our method is suitable for delayed and centralised
CTC analysis which could help recruiting patients for
major clinical trials. In this setting it would be advanta
geous compared to fixation of blood which allows
CTC processing delayed by only several days rather
than long term biobanking. We are currently testing if
cryopreservation is also able to overcome limitations
associated with using fixative for molecular downstream analysis of CTCs that involves nucleic acid
[4,5]
extraction .
In conclusion, we have tested a robust PBMC cryopre
servation protocol that allows successful CTC isolation
even 2 years post freezing. Cryopreservation of CTCs is
feasible, with a small loss of tumor cells predominantly
in samples with a high CTC load. Enumeration of CTCs
from cryopreserved samples remained a clinically im
portant prognostic biomarker. Cryopreservation may
assist with the wider incorporation of CTC collection
and analysis in biobanking, retrospective studies, and
large international clinical trials, by facilitating specimen
storage, bulk transporting, and batch processing. It
may also help to develop diagnostic settings that can
service even remote patients with diagnostic CTC data
potentially relevant for their disease management.

ARTICLEHIGHLIGHTS
HIGHLIGHTS
ARTICLE
Research background

A persisting challenge to the field of circulating tumor cell (CTC) research is the
requirement for prompt analysis of samples at specialised centres. This has
presented significant logistical challenges to researchers, compounded by the
significant expertise, time and laboratory resources required for CTC analysis.

Research motivation

Current methods to overcome this issue, such as fixation of blood samples,
extend the time for CTC processing for several days, but may interfere with
downstream molecular analyses.
Cryopreservation of patient samples permits the wider incorporation of
CTC collection and analysis in biobanking, retrospective studies, and large
international clinical trials, by facilitating specimen storage, bulk transporting,
and batch processing. However, up to now, there has been little research in
how cryopreservation affects CTC recovery, and whether cryopreservation
retains predictive value of CTCs.

Research objectives

The primary objective of our study was to investigate the feasibility and reliability
of delayed CTC isolation from cryopreserved peripheral blood mononuclear
cells (PBMCs) layer. This was determined by percentage of CTC loss during
cryopreservation and thawing, and clinical validity of CTC enumeration from
cryopreserved samples.

Research methods

CTCs were isolated from 7.5 mL blood samples collected from patients with
gastroesophageal adenocarcinoma using EpCAM based immunomagnetic
capture with the IsoFlux platform. CTC loss with cryopreservation was
determined by comparing CTC enumeration from matched cryopreserved
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and freshly processed blood samples collected during the same blood draw.
CTCs isolated from pre-treatment cryopreserved PBMCs were examined for
association with clinicopathological variables and survival outcomes.

9

Research results

We found a minor loss of tumor cells in matched cryopreserved and freshly
processed samples, mostly in samples with high CTC counts. A high CTC
count isolated from cryopreserved PBMCs remained a statistically significant
independent prognostic factor in gastroesophageal cancer.

10

Research conclusions

Our study demonstrates a feasible and robust protocol facilitating CTC isolation
from cryopreserved PBMCs even after 2 years post freezing. Our results have
immediate applicability in the design and conduct of translational studies,
as it facilitates incorporation of CTC analysis in large international trials and
biobanking projects.

11

Research perspectives

12

There is an increasing variety of techniques used for CTC isolation described
in the literature. While the current work confirms the reliability of CTC isolation
from cryopreserved samples using immunomagnetic separation, further work
needs to be undertaken to confirm its suitability for other isolation approaches.

13
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